Zynerba Pharmaceuticals (NASDAQ:ZYNE)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued to investors on Monday.
A number of other brokerages have also recently commented on ZYNE. ValuEngine cut Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, February 4th. Cantor Fitzgerald set a $21.00 price target on Zynerba Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, December 5th. Finally, Zacks Investment Research raised Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a research report on Saturday, January 19th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $13.38.
Shares of Zynerba Pharmaceuticals stock opened at $5.57 on Monday. Zynerba Pharmaceuticals has a 12 month low of $2.75 and a 12 month high of $12.50. The stock has a market cap of $101.98 million, a P/E ratio of -2.13 and a beta of 4.93.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last announced its earnings results on Monday, March 11th. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.21. The firm had revenue of $0.09 million for the quarter. As a group, equities analysts anticipate that Zynerba Pharmaceuticals will post -2.12 earnings per share for the current fiscal year.
A number of hedge funds have recently bought and sold shares of ZYNE. Campbell Capital Management Inc. acquired a new stake in Zynerba Pharmaceuticals in the 4th quarter valued at about $510,000. Vanguard Group Inc raised its position in Zynerba Pharmaceuticals by 23.8% in the 3rd quarter. Vanguard Group Inc now owns 651,400 shares of the company’s stock valued at $5,316,000 after purchasing an additional 125,327 shares in the last quarter. Vanguard Group Inc. raised its position in Zynerba Pharmaceuticals by 23.8% in the 3rd quarter. Vanguard Group Inc. now owns 651,400 shares of the company’s stock valued at $5,316,000 after purchasing an additional 125,327 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in Zynerba Pharmaceuticals in the 3rd quarter valued at about $612,000. Finally, BlackRock Inc. raised its position in Zynerba Pharmaceuticals by 25.2% in the 3rd quarter. BlackRock Inc. now owns 298,355 shares of the company’s stock valued at $2,435,000 after purchasing an additional 59,998 shares in the last quarter. 12.86% of the stock is currently owned by institutional investors.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.
Read More: Net Asset Value
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.